| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 28 Jul 2025 | 50 | 35% | 34% | 31% | 22% |
| 01 Jul 2023 - 31 Dec 2023 | 30 Jan 2024 | 42 | 41% | 37% | 22% | 27% |
| 01 Jan 2023 - 30 Jun 2023 | 20 Jul 2023 | 42 | 41% | 37% | 21% | 27% |
| 01 Jul 2022 - 31 Dec 2022 | 27 Jan 2023 | 40 | 43% | 37% | 20% | 24% |
| 01 Jan 2022 - 30 Jun 2022 | 15 Jul 2022 | 40 | 45% | 34% | 21% | 27% |
| 01 Jul 2021 - 31 Dec 2021 | 31 Jan 2022 | 40 | 47% | 31% | 22% | 28% |
| 01 Jan 2021 - 30 Jun 2021 | 29 Jul 2021 | 46 | 41% | 26% | 33% | 28% |
| 01 Jul 2020 - 31 Dec 2020 | 29 Jan 2021 | 41 | 44% | 29% | 27% | 31% |
| 01 Jan 2020 - 30 Jun 2020 | 31 Jul 2020 | 45 | 42% | 26% | 32% | 31% |
| 01 Jul 2019 - 31 Dec 2019 | 30 Jan 2020 | 38 | 54% | 26% | 20% | 36% |
| 01 Jan 2019 - 30 Jun 2019 | 19 Jul 2019 | 41 | 52% | 18% | 30% | 40% |
| 01 Jul 2018 - 31 Dec 2018 | 25 Jan 2019 | 41 | 48% | 28% | 24% | 34% |
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 | 39 | 24% | 51% | 25% | 40% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
The preferred BMS terms for 3rd party vendors are default to 90 days. Payment terms are outlined in contracts with suppliers. Where a contract is not negotiated, the payment terms will be clearly stated on the Purchase Orders (POs) sent to suppliers. Any changes to the payment terms would require a contract amendment. For Health Care Professionals the standard payment terms are immediate, therefore meeting these terms are difficult to achieve when we consider time to send the invoice, process, approve and release for payment, currently 72% of the above reported late payments are due to Immediate payment terms. Intercompany transactions may also negatively impact the On-time payment percentage due to the Intercompany monthly netting schedule (a further 10% of late payments).
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
BMS has a dedicated Accounts Payable helpdesk in the event of a dispute with a supplier that offers them support through to query resolution. This query can be raised via email at frontoffice-UK@bms.com. If needed the query is then forwarded to the BMS contact (contract monitor or requisitioner) for further investigation. During the COVID pandemic, suppliers are advised to use email to reach the team, they have also been encouraged to submit paper invoices by email, as there had been some slight delays with paper invoice processing due to site access restrictions for collection/scanning into the processing pipeline, best efforts have been made to minimise the impact to payments.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Bristol-Myers Squibb Pharmaceuticals Limited is the UK affiliate of the global pharmaceutical group Bristol-Myers Squibb. Its registered activity is listed as manufacture of basic pharmaceutical products. The company operates a UK medical information service providing details on treatments such as Opdivo, Eliquis, Yervoy, Sprycel and Revlimid, covering areas including adverse events, dosage, drug interactions and availability. It handles enquiries from healthcare professionals and the public via phone and an online medical information library, and directs broader queries to the wider group's global medical information channels. The entity is based in Buckinghamshire and forms part of the group's UK operations supporting its pharmaceutical products rather than an independent trading business.
Generated from the company's website and Companies House records. Sources: bmsmedinfo.co.uk